281 related articles for article (PubMed ID: 32946658)
1. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
3. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
4. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
Rausch CR; DiPippo AJ; Bose P; Kontoyiannis DP
Clin Infect Dis; 2018 Oct; 67(10):1610-1613. PubMed ID: 29771293
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
7. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
8. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
Fung M; Schwartz BS; Doernberg SB; Langelier C; Lo M; Graff L; Tan M; Logan AC; Chin-Hong P; Babik JM
Clin Infect Dis; 2018 Sep; 67(7):1142-1143. PubMed ID: 29617983
[No Abstract] [Full Text] [Related]
10. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
[TBL] [Abstract][Full Text] [Related]
11. Real-world use-Isavuconazole at a large academic medical center.
Hassouna H; Athans V; Brizendine KD
Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
15. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
Garcia-Vidal C
Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
[TBL] [Abstract][Full Text] [Related]
16. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
17. New Perspectives on Antimicrobial Agents: Isavuconazole.
Lewis JS; Wiederhold NP; Hakki M; Thompson GR
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0017722. PubMed ID: 35969068
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
Schwartz S; Cornely OA; Hamed K; Marty FM; Maertens J; Rahav G; Herbrecht R; Heinz WJ
Med Mycol; 2020 Jun; 58(4):417-424. PubMed ID: 31613363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]